Evidence that the novel receptor FGFRL1 signals indirectly via FGFR1 by Amann, Ruth & Trueb, Beat
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  32:  983-988,  2013
Abstract. Fibroblast growth factor (FGF) receptor-like 
protein 1 (FGFRL1) is a recently discovered member of the 
FGF receptor (FGFR) family. Similar to the classical FGFRs, 
it contains three extracellular immunoglobulin-like domains 
and interacts with FGF ligands. However, in contrast to the 
classical receptors, it does not contain any intracellular tyrosine 
kinase domain and consequently cannot signal by transphos-
phorylation. In mouse kidneys, FgfrL1 is expressed primarily at 
embryonic stages E14-E15 in regions where nascent nephrons 
develop. In this study, we used whole-mount in situ hybridiza-
tion to show the spatial pattern of five different Fgfrs in the 
developing mouse kidney. We compared the expression pattern 
of FgfrL1 with that of other Fgfrs. The expression pattern of 
FgfrL1 closely resembled that of Fgfr1, but clearly differed 
from that of Fgfr2-Fgfr4. It is therefore conceivable that FgfrL1 
signals indirectly via Fgfr1. The mechanisms by which FgfrL1 
affects the activity of Fgfr1 remain to be elucidated.
Introduction
The fibroblast growth factor signaling system plays an impor-
tant role in the development of most multicellular animals. 
It controls the proliferation, differentiation, migration and 
apoptosis of virtually all cell types. The genomes of mice 
and humans code for 22 different FGF ligands (FGF1-FGF23, 
FGF15=FGF19) that can interact with four different FGF 
receptors (FGFRs; FGFR1-FGFR4) (1,2). The FGFs bind 
together with heparan sulfate to either one of the four recep-
tors and trigger, via transphosphorylation, several intracellular 
signaling cascades, such as the mitogen-activated protein 
kinase (MAPK)/Erk, the phosphoinositide 3-kinase (PI3K)/
Akt, the Jak/Stat and the phosphoinositide phospholipase C 
(PLC)γ pathway.
All FGFRs contain three extracellular immunoglobulin-
like domains (Ig domains 1-3), a single transmembrane domain 
and an intracellular tyrosine kinase domain (2). Alternative 
splicing contributes to the complexity of the system. Each 
of the receptors FGFR1, FGFR2 and FGFR3 occurs in two 
different splice variants that differ by the precise amino acid 
sequence of Ig domain 3. At the genomic level, this domain 
is encoded by three different exons, namely exons IIIa, IIIb 
and IIIc. Exon IIIa codes for the first half of Ig domain 3 and is 
used for all splice variants, but exons IIIb and IIIc are used in 
a mutually exclusive manner to give rise to two different splice 
variants, the b and the c variants. A total of seven different 
receptors can therefore be generated, FGFR1b, FGFR1c, 
FGFR2b, FGFR2c, FGFR3b, FGFR3c and FGFR4 (1,2). The 
b splice variants are primarily expressed in epithelial tissues, 
the c variants mainly in mesenchymal tissues.
The metanephric (permanent) kidney of mammals is 
formed by two different tissues, the metanephric mesenchyme 
and the ureteric bud (3,4). In mice, the development of the 
metanephric kidney begins on embryonic day E10.5 when 
the ureteric bud invades the metanephric mesenchyme. By a 
series of reciprocal interactions, the metanephric mesenchyme 
induces the ureteric bud to branch in a stereotypical fashion, 
while the ureteric bud induces the metanephric mesenchyme 
to condense around its tips and to undergo a mesenchymal-
to-epithelial conversion that leads to the formation of renal 
vesicles. The renal vesicles develop further into comma- and 
s‑shaped bodies and finally form functional nephrons. Gene 
expression profiling has revealed that the developing mouse 
kidney expresses Fgfs 1, 7, 8, 9, 10, 12 and 20 (5).
In the year 2000, we discovered a fifth FGFR that we 
termed FGF receptor-like protein 1 (FGFRL1) (6). This 
receptor contains three Ig domains and a single transmembrane 
domain similar to the classical FGFRs. However, it lacks the 
tyrosine kinase domain and instead contains a short unrelated 
sequence at the intracellular side that ends with a histidine-rich 
domain (7-10). FGFRL1 is expressed primarily in cartilage 
and developing bones, and at lower levels in many other organs 
including kidneys and muscles. Mice with a targeted disrup-
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tion of the novel receptor-like gene (knockout mice) develop 
to term and are born alive (11,12). However, these animals die 
immediately after birth and show severe kidney dysgenesis 
or kidney agenesis due to the lack of renal vesicles (13). We 
confirmed that FgfrL1 is in fact expressed in renal vesicles 
and all nephrogenic structures during the early steps of kidney 
development (14,15).
The molecular mechanisms behind the involvement of 
FGFRL1 in FGF signaling have not yet been elucidated. It 
cannot signal by transphosphorylation as it does not contain 
any intracellular tyrosine kinase domain. When mRNA for 
FGFRL1 was injected into blastomers of Xenopus embryos, it 
interfered with FGF signaling and led to gastrulation defects 
that affected the trunk and tail of the embryos (16). This 
effect was overcome by the co-injection of mRNA for FGFR1. 
We therefore concluded that FGFRL1 may act as a decoy 
receptor that binds and neutralizes FGF ligands. However, this 
hypothesis was challenged by more recent findings obtained 
with FgfrL1 null mice. A comparison of the mRNA profiles 
from wild-type and knockout animals using gene microarrays 
revealed that the lack of FgfrL1 was not compensated for by 
another Fgfr or by any downstream signaling molecule (14). 
Furthermore, the phenotype of our knockout animals was 
strikingly similar to the phenotype of animals with a condi-
tional deletion of Fgf8, which also lack any nephrons in their 
metanephric kidneys (13,17,18). If FgfrL1 served as a simple 
decoy receptor for Fgf ligands one would expect to observe 
more, and not less Fgf signaling in our knockout animals and 
consequently an increased, rather than a decreased, number of 
nephrogenic structures and/or ureteric buds.
To gain a better understanding of the working mechanisms 
of FgfrL1, we decided to compare the exact expression pattern 
of FgfrL1 with that of the other Fgfrs. We hypothesized that a 
particular receptor would show an expression pattern similar 
to that of FgfrL1 if FgfrL1 is involved, directly or indirectly, 
in its signaling cascade. We found that the FgfrL1 expression 
pattern greatly resembled that of Fgfr1, but clearly differed 
from that of Fgfr2-Fgfr4, suggesting that FgfrL1 may partici-
pate in Fgfr1 signaling.
Materials and methods
Animals. Kidneys were obtained from mice (strain C57BL/6) 
bred at our local animal facility. For a timed pregnancy, the 
noon of the day, at which a vaginal plug could be detected, was 
counted as E0.5. All animal experiments were approved by the 
Swiss Federal Veterinary Office (BVET) (BE84/12).
RNA preparation and northern blotting. Kidneys were dissected 
from mouse embryos and immediately placed into RNA-later 
buffer (Sigma, St. Louis, MO, USA). In order to obtain 
enough RNA, kidney rudiments of early developmental stages 
(E12.5-E14.5) were pooled from 20-30 individual embryos. RNA 
was prepared using the GeneElute mammalian total RNA kit 
from Sigma and separated on 1% agarose gels in the presence of 
1 M formaldehyde. The resolved bands were transferred from the 
gel to a nylon membrane by vacuum blotting. The membrane was 
hybridized at 42˚C with radioactively labeled cDNA probes in a 
buffer containing 50% formamide. These probes were labeled 
by the random primed oligolabeling method with [α-32P] dCTP. 
After overnight hybridization, the blot was washed at regular 
stringency [1X standard saline citrate (SSC)] and exposed to 
X‑ray film (Carestream Kodak BioMax MS; Sigma).
Hybridization probes for the canonical Fgfrs were generated 
by PCR utilizing cDNA prepared from E16.5 mouse kidneys and 
the primer pairs listed in Table I. Probes for Fgfr1-Fgfr3 were 
selected in a manner that they hybridized equally well with the 
b and the c splice variants. The PCR fragments were inserted 
into the BamHI/XbaI site of the expression vector pSPT19 
(Roche Applied Science, Basel, Switzerland). The probe for 
FgfrL1 corresponded to an XbaI/BamHI fragment derived from 
the full-length cDNA sequence (9), which was subcloned into 
pSPT19. The final probes encompassed nucleotides 766‑1554 
(corresponding to amino acids 7-269) of Fgfr1 (NM_010206), 
nucleotides 1336-1979 (amino acids 57-271) of Fgfr2 
(NM_010207), nucleotides 374-1093 (amino acids 23-262) 
of Fgfr3 (NM_008010), nucleotides 503-1242 (amino acids 
115-360) of Fgfr4 (NM_008011), nucleotides 661-1417 (amino 
acids 190-441) of FgfrL1 (AJ293947) and nucleotides 211-899 
(amino acids 26-255) of calbindin (NM_009788). The reading 
frame and authenticity of all constructs were verified by DNA 
sequencing.
Whole-mount in situ hybridization. Whole-mount in situ 
hybridization was performed using E15.5 mouse kidneys 
following the protocol provided in the GUDMAP gene expres-
sion database (http://www.gudmap.org/Research/Protocols/
McMahon.html). Riboprobes were generated from cDNA 
sequences cloned into pSPT19 (see above) by transcription in 
the presence of digoxigenin-labeled UTP using the SP6/T7 DIG 
RNA Labeling kit from Roche as previously described (13). 
Kidneys were dissected from 15.5-day-old embryos and 
fixed overnight with 4% paraformaldehyde (PFA). The tissue 
was dehydrated by serial treatment with methanol/phosphate 
buffer (25, 50, 75 and 100% methanol in PBS containing 0.1% 
Tween-20). The specimens were rehydrated, bleached for 
30 min with 6% hydrogen peroxide and digested for 15 min 
with 10 µg/ml proteinase K. Subsequently, the samples were 
fixed with 0.2% glutaraldehyde/4% PFA, pre‑hybridized at 68˚C 
for 2 h in hybridization buffer (50% formamide, 5X SSC, 1% 
SDS, 50 µg/ml t-RNA from yeast, 50 µg/ml heparin) and then 
hybridized overnight with the riboprobes. Following washing 
with 50% formamide, 5X SSC, 1% SDS at 65˚C, the samples 
were blocked for 2 h at room temperature with 3% bovine serum 
albumin in Tris-buffered saline and then incubated with anti-
digoxigenin antibodies conjugated with alkaline phosphatase 
(Roche, 1:2,000). After extensive washing, the hybridization 
signal was developed with BM Purple (Roche) for 7-78 h.
Results
Analysis of Fgfr expression by northern blotting. The expres-
sion of the four classical receptors was analyzed by northern 
blotting with samples from embryonic kidneys at stage E15.5. 
Special care was taken so that the four hybridization probes 
had a similar specific radioactivity to allow the direct compar-
ison of the resulting hybridization signals between the four 
probes. Moreover, the sequences of the probes were selected 
in a manner that the probes hybridized equally well with the b 
and the c splice variants of the receptors.
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A particularly strong hybridization signal was obtained 
with the probe for Fgfr1 (Fig. 1). This result suggests that Fgfr1 
is the principal receptor in the developing mouse kidney at 
stage E15.5. A strong signal was also observed with the probe 
for Fgfr2. However, in this case the resulting band was broader 
and fuzzier, possibly due to the presence of several distinct 
mRNA splice variants and/or different polyadenylation sites. 
By contrast, the signals for Fgfr3 and Fgfr4 were extremely 
weak and could be detected only after extended exposure of 
the northern blots, indicating that these receptors are expressed 
in the kidneys at very low levels during early development. 
The electrophoretic mobility of all the positive bands was 
consistent with the size of the four mRNAs predicted from 
their cDNA sequences (Fgfr1 5,000 bp, Fgfr2 5,200 bp, Fgfr3 
4,500 bp and Fgfr4 3,500 bp). Our northern blotting experi-
ment also demonstrated that no unexpected crossreaction 
occurred between each of the probes and the four receptors.
The expression of FgfrL1 was analyzed on a separate 
northern blot containing RNA from kidneys at five different 
developmental stages (Fig. 2). A band of 3,000 nt was observed 
consistent with the published size of the mouse FgfrL1 
Figure 1. Analysis of fibroblast growth factor receptor (Fgfr) expression in the 
mouse kidney. Aliquots (10 µg) of total RNA from mouse kidneys at E15.5 
were resolved in parallel on an agarose gel, transferred to a nylon membrane 
and individually hybridized with radiolabeled probes for Fgfr1, Fgfr2, Fgfr3 
and Fgfr4 as indicated. The migration positions of the ribosomal RNAs are 
indicated in the margin. As a loading control, the ethidium bromide stained 
28S ribosomal RNA is shown.
Table I. Primers used for preparation of hybridization probes.
Primer Sequence Accession no.
Calb1 up ATGGATCCGACGGAAGTGGTTACCTGGA
Calb1 low TATCTAGATAAGAGCAAGGTCTGTTCGGTA NM_009788
Fgfr1 up GTGGATCCTCTTCTGGGCTGTGCT
Fgfr1 low ATTCTAGACCAGGGCCACTGTCTTGT NM_010206
Fgfr2 up GAGGATCCACCAACCAAATACCAAATC
Fgfr2 low TGTCTAGACCGTTCAACGACATCGAG NM_010207
Fgfr3 up GAGGATCCTGGTCCAGAGCAGCG
Fgfr3 low ACGTCTAGACCTAGAATGGCTGTCTGG NM_008010
Fgfr4 up GTGGATCCTGGATGACTCCTTAACCTC
Fgfr4 low TGTCTAGAGGGGTTGCTGTTGTCCAC NM_008011
Underlined bases indicate restriction sites used for subcloning.
Figure 2. Analysis of FgfrL1 expression during early kidney development. 
Aliquots of total RNA from mouse kidneys of different developmental 
stages were resolved on an agarose gel, transferred to a nylon membrane and 
hybridized with a probe for FgfrL1. The migration positions of the ribosomal 
RNAs are indicated in the margin. As a loading control, the ethidium bromide 
stained 28S ribosomal RNA is shown.
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mRNA (8,9). This band was barely detectable at stage E12.5 
but became clearly visible at E14.5 and E15.5 and decreased 
thereafter. This result suggests that FgfrL1 is required during 
the early stages of kidney development when renal vesicles and 
comma- and s-shaped bodies develop (3,4).
Analysis of Fgfr expression by in situ hybridization. The 
spacial distribution of the FgfrL1 mRNA was compared with 
the distribution of the four classical receptors by whole-mount 
in situ hybridization of entire kidneys at stage E15.5 (Fig. 3). 
The cDNA sequences that had been used above for the northern 
blotting experiment were utilized for the preparation of bioti-
nylated riboprobes. The hybridization of a control kidney 
with a probe for calbindin yielded a pattern of clover leaf-like 
structures consistent with the expression of this marker gene 
in all ureteric buds. Hybridization of a kidney with a probe 
for FgfrL1 produced a completely different pattern. A fine 
punctate or dotted distribution was observed, which was 
consistent with expression of the FgfrL1 gene in renal vesicles 
and nascent nephrogenic structures. Hybridization with a 
probe for Fgfr1 produced a very similar pattern, suggesting 
that the expression of Fgfr1 and FgfrL1 overlapped to a large 
extent. Hybridization with a probe for Fgfr2 revealed a pattern 
resembling the distribution of calbindin. However, the signal 
of Fgfr2 was more diffuse, particularly at the ureteric tips, 
suggesting that Fgfr2 expression was not confined exclusively 
to the ureteric bud, but occurred to some extent also in nascent 
nephrons. The signals obtained with the probes for Fgfr3 and 
Fgfr4 were extremely weak. They both revealed distributions 
that were more complex than the above-mentioned expression 
patterns.
The progression of the enzymatic reaction that was used 
for development of the signal shown in Fig. 3 may provide 
a crude measure of the relative expression levels of the four 
receptors. A robust signal was obtained after 7 h with the 
probe for Fgfr1 and after 20 h with that for Fgfr2, indicating 
that these two receptors are the major Fgf signaling proteins 
in the developing kidney at E15.5. To obtain a signal for Fgfr3 
and Fgfr4, the color reaction had to proceed for 78 h, again 
suggesting that these receptors are expressed at extremely low 
Figure 3. Expression patterns of the five fibroblast growth factor receptors (Fgfrs) in mouse kidneys. Kidneys at stage E15.5 were stained by whole‑mount 
in situ hybridization with riboprobes for Fgfr1 (R1), Fgfr2 (R2), Fgfr3 (R3), Fgfr4 (R4), FgfrL1 (RL1) and calbindin 1 (Calb) as indicated. The results dem-
onstrated that the expression pattern of FgfrL1 looked very similar to that of Fgfr1 and the pattern of Fgfr2 similar to that of calbindin. Fgfr3 and Fgfr4 were 
expressed at very low levels and revealed more complex expression patterns. 
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levels. The development time for FgfrL1 was 19 h, comparable 
to that of Fgfr2.
Discussion
In this study, we used the whole-mount in situ hybridiza-
tion technique to show the spacial expression pattern of five 
different Fgfrs in the developing mouse kidney. This technique 
yields information about the three-dimensional distribution 
of the corresponding mRNAs in the cortex of the kidney, 
whereas in situ hybridization of thin sections would show 
only a two-dimensional expression pattern. Whole-mount 
in situ hybridization appears to be more sensitive than section 
hybridization as it accumulates signals from the depth of the 
kidney cortex, which offers an extra advantage when expres-
sion levels are very low. In fact, section in situ hybridization 
did not yield convincing data with probes for Fgfr3 and Fgfr4. 
Moreover, the signal obtained with FgfrL1, the fifth Fgfr, 
proved to be extremely weak by section hybridization and had 
to be electronically enhanced for visualization in a previous 
publication (14). By contrast, whole-mount in situ hybridiza-
tion with FgfrL1 yielded robust signals that did not have to be 
enhanced.
In this study, we demonstrate that Fgfr1 and Fgfr2 are the 
major receptors of the Fgf signaling system expressed in the 
early stages of developing kidneys. On the other hand, the 
expression of Fgfr3 and Fgfr4 was very low, raising doubts about 
the functional significance of these receptors during kidney 
development. This observation is in accordance with the results 
obtained from experiments using knockout mice (Table II). 
The disruption of the genes for Fgfr3 and Fgfr4, either alone 
or in concert, did not produce any altered phenotype in the 
mouse kidneys (19,20). Fgfr3 and Fgfr4 knockout animals were 
viable and only Fgfr3-null mice showed an obvious phenotype 
with abnormally long bones (19). By contrast, the disruption of 
each of the receptors Fgfr1 and Fgfr2 caused lethality at very 
early embryonic stages before nephrogenesis was initiated, 
preventing the analysis of these genes during kidney forma-
tion (21-24). Thus, a conditional targeting approach had to be 
used for these cases. Interestingly, the conditional disruption 
of Fgfr1 in the metanephric mesenchyme or in the ureteric 
bud did not yield any overt phenotype (25-27). Likewise, the 
conditional deletion of Fgfr2 in the metanephric mesenchyme 
did not produce any severe alterations (25). Only the condi-
tional deletion of Fgfr2 in the ureteric bud produced animals 
with abnormalities in ureteric branching, but the phenotype 
was relatively mild and the animals were viable (26,27). The 
phenotype was more severe when both receptors were deleted 
in concert. After the compound deletion of Fgfr1 and Fgfr2, no 
metanephric mesenchyme formed, suggesting that either Fgfr1 
or Fgfr2 is required for nephrogenesis but that the two receptors 
can substitute for one another (25,27). The observations made 
with the four classical receptors are in sharp contrast with the 
targeted disruption of the fifth receptor. The global deletion of 
FgfrL1 yielded animals that specifically lacked the metanephric 
kidneys and died at birth (13). At E10.5, the ureteric bud of 
these animals still invaded the metanephric mesenchyme, but 
branching stopped after the T-state and no renal vesicles were 
formed. It is intriguing to note that the targeted disruption of 
FgfrL1, but not of any other Fgfr, completely inhibited kidney 
development, although FgfrL1 is expressed at very low levels 
in the kidneys.
In this study, we demonstrated that the spacial distribution 
of FgfrL1 mRNA closely resembled that of Fgfr1, but clearly 
differed from that of Fgfr2-Fgfr4. FgfrL1 cannot signal on its 
own as it lacks the intracellular tyrosine kinase domain. Since 
it still interacts with Fgf ligands, it is likely that it indirectly 
modulates the Fgf signaling of another receptor. Thus, we 
concluded that this other receptor may be Fgfr1, since only this 
receptor shows a similar distribution in developing kidneys.
Originally we (7,16), as well as others (8) have speculated 
that FgfrL1 may act as a decoy receptor that binds and neutral-
izes Fgf ligands. However, recent results obtained by DNA 
microarray profiling suggest the opposite (14). The disrup-
tion of the FgfrL1 gene in mice was not accompanied by the 
specific upregulation of any target genes that are known to be 
controlled by Fgf signaling. Yet, such an upregulation would 
be expected if FgfrL1 acted as a simple decoy receptor. By 
contrast, we found that approximately 50 gene products were 
significantly downregulated upon the disruption of FgfrL1 
expression, including wingless-type MMTV integration site 
family member 4 (Wnt4), dickkopf 1 (Dkk1), early growth 
response 1 (Egr1), Fgf8 and LIM homeobox 1 (Lhx1) (14). It 
is therefore likely that FgfrL1 acts as a positive regulator of 
Fgf signaling, rather than as a decoy receptor, at least in the 
kidneys.
It has been demonstrated that the developing kidneys of 
mice express Fgfs 1, 7, 8, 9, 10, 12 and 20 (5). Of these ligands, 
Table II. Phenotype of embryos and kidneys after the targeted inactivation of Fgfrs.
 Mouse phenotype Kidney phenotype
Receptor (general KO) (conditional KO for Fgfr1, Fgfr2)
Fgfr1 Lethal E7.5-E9.5 Normal
Fgfr2 Lethal E4-E10 Abnormalities in ureteric branching
Fgfr3 Abnormally long bones Normal
Fgfr4 Normal Normal
FgfrL1 Perinatally lethal (P0-P1) Absence of nephrons
KO, knockout mice.
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FgfrL1 appears to interact only with Fgf8 (16). One mechanism 
of action may therefore be that FgfrL1 binds to Fgf8 and serves 
as a co-receptor, presenting this ligand to Fgfr1. The activation 
of Fgfr1 would then lead to downstream signaling events that 
ultimately allow the survival of cells in the induced meta-
nephric mesenchyme and the inhibition of apoptosis. In fact, 
the phenotypes of FgfrL1- and Fgf8-null mice are intriguingly 
similar (13,17,18). In both animal models, the development 
of nephrons is inhibited and increased apoptosis is observed 
in the metanephric mesenchyme. Another possibility may 
be that FgfrL1 is involved in the conversion of the induced 
metanephric mesenchymal cells into renal epithelial cells by 
controlling the alignment of mesenchymal cells. We have 
previously demonstrated that FgfrL1 can serve as an adhesion 
molecule if coated on bacterial plastic dishes (28). Moreover, 
it promotes cell-cell fusion if expressed at the surface of 
HEK293 cells and if mixed with CHO cells (29). It is possible 
that this cell fusion activity simply represents the ultimate 
stage of very tight cell-cell adhesion. FgfrL1 may therefore 
control the condensation of the metanephric mesenchyme 
around the ureteric tips by bringing together mesenchymal 
cells in an epithelial-like manner. The mechanisms by which 
Fgfr1 and Fgf8 are involved in this process are not yet fully 
elucidated. Further experiments are required to differentiate 
between all the possibilities outlined above.
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